WO2015178729A1 - 신규한 시료 내 검출대상물의 검출방법 및 그를 이용한 검출키트 - Google Patents
신규한 시료 내 검출대상물의 검출방법 및 그를 이용한 검출키트 Download PDFInfo
- Publication number
- WO2015178729A1 WO2015178729A1 PCT/KR2015/005191 KR2015005191W WO2015178729A1 WO 2015178729 A1 WO2015178729 A1 WO 2015178729A1 KR 2015005191 W KR2015005191 W KR 2015005191W WO 2015178729 A1 WO2015178729 A1 WO 2015178729A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- sample
- complex
- support
- detection
- bridge
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/531—Production of immunochemical test materials
- G01N33/532—Production of labelled immunochemicals
- G01N33/533—Production of labelled immunochemicals with fluorescent label
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54306—Solid-phase reaction mechanisms
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
Definitions
- the present invention relates to a novel detection method of a detection object in a sample and a detection kit using the same.
- Testosterone is a male hormone with secondary sexual characteristics, belongs to the steroid hormones of the androgen group, and is mainly secreted from the gonads. Testosterone is associated with (1) decreased sexual desire and decreased erection and frequency of menopausal men, (2) intellectual activity, cognitive function, decreased spatial perception, mood changes in fatigue, mood and anxiety, (3) sleep disorders, (4) Decreased fat mass associated with a decrease in muscle mass and muscle strength, (5) increased visceral fat, (6) reduced body hair and skin disease, and (7) increased osteopenia and fracture risk due to decreased bone density.
- the testosterone is diagnosed mainly by analyzing the amount of testosterone present in the blood.
- the increased testosterone is associated with androgen resistance, ovarian cancer, testicular cancer, ngeni tal adrenal hyperplasia or precocious puberty. It is associated with chronic disease, pituitary abnormalities, delayed puberty, testicular abnormalities, or uncancerous tumors consisting of pituitary cells that are overproduced.
- testosterone present in vivo is not present in a free state, but mostly in a state associated with a protein. In other words, the free state is only 2-3% of testosterone, 44-65% It is associated with Sex Hormone Binding Globulin (SHBG) and 33-54% is associated with albumin. For this reason it is difficult to detect testosterone present in the blood.
- SHBG Sex Hormone Binding Globulin
- the detection method to be used in the present invention is a competitive iterative (compet it ive assay), using a gold nanoparticles as a medium by amplifying the measurement signal by increasing the reaction sensitivity than the conventional method using a competitive reaction, such as testosterone
- the purpose of this study is to establish a method for detecting micromolecules more accurately.
- the present inventors made diligent research efforts to develop a novel method for detecting a target in a sample.
- the detection object in the sample is combined with the 'bridge complex', whereby the 'bridge complex' and the 'competitor carrier complex' that generates a signal
- the method does not bind to the same binder on the support, and as a result, a signal is not generated on the support, thereby developing a method for accurately detecting a target in a sample.
- the present invention Unlike the conventional fluid flow detection method (l iquid f low assay), which is applied to an analysis immediately after separating a nontarget material bound to a detection object using an acidification or an analog of the detection object, By contacting the detection object in the sample isolated from the binding protein with particles in which a specific eye binder (eg, an antibody) was bound to the detection object, a complex of the detection object, the binder and the particle was also applied to the flow analysis. By performing the above process, the reaction of the detection object and the binder was induced to complete the loading sample in a state suitable for the detection method of the present invention, and thus it was confirmed that more accurate qualitative and quantitative analysis was possible.
- a specific eye binder eg, an antibody
- Another object of the present invention is to provide a detection kit of a detection object in a novel sample.
- the present invention provides a method for detecting a target object in a sample, comprising the following steps:
- a sample may contain (i) binding equivalents that have the same binding properties as the detection object and generate a signal.
- Contact ing with a 3 ⁇ 4 " body (a compet i tor carr ier complex having an analyte and being capable of generat ing signal) and (ii) a binder complex with a binder that specifically binds to the target If a target is present in the sample, the target in the sample binds to the bridge complex; (b) contacting the resultant of step (a) with the same binder having the same binding properties as the detection object bound to the test zone on the support;
- the detection object is present in the sample
- the bridge complex to which the detection object in the sample is bound does not bind to the same binder on the support and no signal is generated on the support, and the detection object is not present in the sample
- the bridge complex is bonded to the same bond on the support and the competitor carrier complex is bonded to the bridge complex to generate a signal on the support;
- step (C) measuring the intensity of the signal generated from the competitor carrier complex in the result of step (b).
- the present inventors have diligently researched to develop a novel method for detecting a target in a sample.
- the target in the sample is competitive with the 'competitor carrier complex that generates a signal.''And thus, the bridge complex to which the detection target is bound does not bind to the same binding on the support, and as a result, no signal is generated on the support, thereby developing a method for accurately detecting the detection target in the sample.
- the method of the present invention is a conventional fluid flow detection method (l iquid f low assay) which is applied to an analysis immediately after separating a nontarget material bound to a detection object using an acidification or an analog of the detection object.
- a binding agent eg, an antibody
- a complex of the detection object, the binding agent, and the particles was applied to the flow analysis.
- the detection method of the present invention is a method for detecting an object present in an analyte by using a competing reaction (compet it ive react ion), the present inventors (i) fluid in a conventional competitive it method (compet it ive assay) In case of binding the detection object to the antibody immobilized on the support in the reaction in the flow (internal reaction), it is difficult to accurately quantitatively analyze because the reaction time between the detection object and the antibody in the sample is insufficient.
- a competitor hormone for example, 2-methoxyestradiol
- a protein for example, globulin or albumin
- Various known methods for separating from the target material can be used.
- the method of the present invention can improve reaction by 1 inducing a sufficient binding reaction between the antibody and the detection object by using a 'bridge complex' that binds the gold nanoparticles and the antibody specific to the detection object, and 2 excellent resolution or resolution (resolut ion) allows the detection object to be separated in a fine concentration range, thereby enabling accurate concentration measurement of the detection object in the sample.
- the method of the present invention can effectively detect small molecules such as hormones and vitamins with small molecular weights.
- sample includes, but is not limited to, an organic substance derived from all mammals and an artificially synthesized organic molecule (organi c molecules) as a substance including a detection object. It is not.
- the sample may be a virus, bacteria, cell or tissue-derived extract, lysate or purified product, blood, plasma, serum, lymph, bone marrow, saliva, ocular fluid, semen, brain extract, spinal fluid, joint fluid, thymus Biological sample contaminants such as fluids, ascites or amniotic fluids, toxins, toxic chemicals, forensic substances Or similar materials.
- organic molecules refers to a molecule having a covalent bond between carbon, nitrogen, oxygen and / or sulfur atoms.
- Organic molecules can be selected from small sized molecules such as carbon monoxide to complex large site molecules such as polymers.
- binding equivalents refers to all biochemical compounds that have the same binding properties as the detection target.
- the detection target and the same conjugate may be a protein, peptide, carbohydrate, lipid, nucleic acid or compound.
- the detection target and the same combination include various known compounds ' chemical hormones and analogues thereof, such as testosterone, thyroid hormone (TSH), human growth hormone, progesterone, chorionic gonadotropin (hCG) and analogue hormones thereof.
- the same binder is testosterone-3-carboxymethyloxime-BSA.
- the detection target and the same binder are compound hormones and compound hormones bound to proteins, and more specifically, testosterone (testosterone) and testosterone bound to sex hormone binding gluobul (SHBG) (testosterone) or testosterone bound to albumin (Albumin).
- SHBG sex hormone binding gluobul
- Albumin testosterone bound to albumin
- the method of the present invention can be widely used to detect not only testosterone but also micromolecules such as vitamin D.
- the term "competitor carrier complex” refers to a complex comprising the same binder and particles or beads, wherein the particles or beads have the same binding properties as the object to be detected. The binding equivalents are combined.
- the particles or beads may generate a signal, for example the particles or beads include nanoparticles, microparticles, nanobeads or microbeads.
- the particles or beads may have a diameter of 200 nm to 1000 nm, and according to the invention the diameter of the particles or beads is 200 nm to 500 nm.
- the competitor carrier complex functions as a complex in which the same binder and the beads are bound, and more particularly, the same binder bound to the beads of the competitor carrier complex may be bound to the antibody bound to the bridge complex.
- the term "binder" is a substance that specifically binds to a detection target, and includes, for example, proteins, peptides, carbohydrates, lipids, nucleic acids, and compounds specific to the detection target.
- the binding agent is an antibody, modified antibody, antibody analogue, aptide, receptor, streptavidin, avidin, neutravidin, aptamer, lectin, substrate, DNA, RNA, lipid or viral protein.
- the binder is an antibody.
- bridge complex refers to a complex including a binder and particles or beads, wherein the particles or beads are bound to a binder that specifically binds to a detection object.
- the binder bound to the bridge complex may bind to the detection target or the same binder in the sample.
- the particles or beads include nanoparticles, microparticles or nanobeads or microbeads.
- the particles or beads may have a diameter of 20 nm to 80 nm, and according to the invention the diameter of the particles or beads is 40 nm to 50 nm.
- the bridge complex is a complex of 'antibody specific for gold nanoparticles and a detection object'.
- the bridge composite may include a plurality of binders per particle.
- Step (a): Contact of Sample, Competitor Carrier Complex and Bridge Complex (i) A sample of the competitor carrier complex (a compet i tor carr ier) bound to the binding equivalents having the same binding properties as the object to be detected. complex) and (ii) contact with a bridge complex to which a binder that binds specifically to the target is bound.
- the detection object in the sample binds to the bridge complex.
- the detection target and the competitor carrier complex in the sample which bind to the bridge complex may react competitively at the same time or may react selectively or sequentially, respectively.
- (i) sample, competitor carrier composite and bridge When contacting the complexes simultaneously, the bridge complex binds to the sample in the sample competitively with respect to the competitor carrier complex.
- the bridging complex binds to the detection object (sample) or the same conjugate (competitor carrier complex) and little competition reaction occurs unlike simultaneous contact.
- a competitor carrier complex may be first bound to a residual binder of a bridge complex after a complex of a target complex and a bridge complex bond in a sample is formed. For example, when the sample and the bridge complex are reacted to form a complex of the object-bridge complex, and then applied to the detection kit of the present invention, the complex is bound to the same conjugate in the test zone, and then the competitor carrier complex is a non-binding antibody of the bridge complex.
- the competitor carrier composite includes colored particles as particles, and a signal is generated directly from the colored particles.
- the chromogenic particles are particles of fluorescent molecules, chromogenic.
- the particles or beads of the competitor carrier complex further comprise a detectable signal generating label and the signal can be generated from the signal generating label.
- signal means a detectable parameter and includes the flow of optical, electrical or magnetic parameters, fluorescence emission, infrared radiation, ultraviolet radiation, chemiluminescence, light reflection and also the degree of absorption of the signal.
- Labels that generate detectable signals include chemicals (e.g. biotin), enzymes (alkaline phosphatase, ⁇ -galactosidase, horse radish peroxidase and cytochrome ⁇ 450 ), radioactive substances (e.g.
- the label may comprise a variety of known fluorescent materials, for example, fluorosane and its derivatives, rhodamine and its derivatives, phycoerythrin, lucifer yellow, B-phytoerythrin, 9-acridine isothiocyanate , Lucifer yellow VS, 4-acetamido-4'-isothio-cyanatostilben-2,2'-disulfonic acid, 7-diethylamino-3- (4'-isothiocyatophenyl) 4-methylcoumarin, succinimidyl-pyrenebutyrate, 4-acetamido-4'-isothiocyanatostilben-2, 2'-disulfonic acid derivative, LC TM -Red 640, LC TM -Red 705 , PC5, Cy5, Cy5.5, lysamine isothiocyanate, erythrosine isothiocyanate, diethylenetriamine pentaacetate, 1-dimethylamin
- the step (a) may include the following sub-steps:
- step (a-1) contacting the sample with the bridge complex treated with a displacement agent to dissociate the compound hormone from the compound hormone bound to the protein; And (a-2) the substep of contacting the resultant of step (a-1) with the competitor carrier complex.
- the displacement agent may be an acid, an alkali, a heavy metal or an organic solvent, a competitor hormone, or the like, as a reagent for separating a compound hormone and a protein.
- the dissociating agent is a competitor hormone (e.g. 2-methoxyestradiol), and the competitor hormone acts competitively against the compound hormone (e.g. testosterone) to bind to the compound hormone (sex Hormone binding globulin or albumin).
- the competitor carrier composite may be located upstream of the test zone on the support prior to performing step (a).
- the sample passes through the test zone where the same compound is bound together with the competitor carrier complex.
- the sample containing the detection object is (i) 'sample zone' into which the sample is put on the support, (ii) 'competitor carrier complex zone' and () bridge complex contacting the competitor carrier composite with the sample And / or a 'test zone' to which the competitor carrier complexes can bind, the three zones may be located on the support in fluid flow order.
- the step (a) may be performed by treating the sample treated with a di spl acement agent that dissociates the compound hormone from the compound hormone bound to the protein. Contacting the bridge complex to obtain a sample / bridge complex reactant, and then applying the sample / bridge complex reactant to the sample zone, wherein step (b) is performed through the fluid flow of the sample cartridge composite reactant and the competitor
- the carrier complex may be moved to the test zone and brought into contact with binding equivalents bound to the test zone.
- Step (b) contact of the same combination of test zones and the result of step (a) followed by the same binding properties having the same binding properties as the detection object bound to the test zone on the support Contact with the bond.
- the bridge complex to which the detection object in the sample is bound does not bind to the same binder on the support and no signal is generated on the support, and the detection object is not present in the sample
- the bridge complex is bonded to the same bond on the support and the competitor carrier complex is bonded to the bridge complex to generate a signal on the support.
- a support is bonded to the same binder, and the same bond exists on the surface of the substrate of one reaction vessel in which a continuous flow of the reaction product is carried out, and the semi-reactor has a microchannel. It's a microcheap.
- the term "support” may be used in the same sense as "sol id substrate, sol id support or sol id phase", and means a non-liquid material. .
- the support is Microchannels can be formed therein and can exist, for example, as membranes, portions of capillaries or as small l ammeter beads flowed / adhered within the microchannels.
- Known materials of this type include hydrocarbon polymers such as polystyrene and polypropylene, glass, metals, and gels.
- the support may be in the form of dipsticks, microtiter plates, particles (such as beads), affinity columns and immunoblot membranes (such as polyvinylidene fluoride membranes) (see, eg, US Pat. No. 5,143). 825, 5,374, 530, 4,908, 305 and 5, 498, 551).
- a signal measuring device is used to measure the intensity of the signal generated from the competitor carrier complex in the result of step (b).
- the signal emitted from the label contained in the competitor carrier complex is measured as a fluorescence signal
- the presence of the detection object can be confirmed by measuring the fluorescence signal of the test zone
- the sample passed through the test zone Quantitative analysis is possible through a series of processes.
- the quantitative analysis of the detection object is carried out by the method described in Republic of Korea Registration No. 10-1353930.
- the microchannel on the support includes a test zone and a reference zone, the same binder is bound to the surface of the test zone, and an animal-derived peptide in the standard zone.
- a detection antibody selected as a substance capable of binding thereto may bind.
- a detection antibody specific for the same binding entity or a detection target may be bound.
- test zone is a compartment included in the microchannel of the support for fluid flow analysis, and the same binder having the same binding properties as the detection object is bound to the surface of the test zone.
- reference zone refers to a compartment included in the microchannel of the support, to which a detection antibody selected as an animal-derived peptide or a substance bindable thereto may bind.
- the surface of the standard zone is bound to an antibody that is specific for the same binder or to the target, so that the same binder or target through the test zone can bind.
- the same conjugate or antibody may be attached to a solid substrate by physical adsorption or chemical adhesion.
- Physical adsorption is carried out by reaction between the solid phase material and the antibody or antigen in the appropriate supernatant.
- the buffer include a phosphate complete solution, a tris-hydrochloride complete solution, and a carbonate buffer solution.
- the reaction is carried out by mixing and maintaining the complete layer at 4-37 ° C., especially at room temperature for a certain time.
- Chemical attachment is feasible by using the carbodiimide method in the peptide attachment method.
- Other chemistries include glutaraldehyde or cyanuric chloride ("peptide synthesis", Maruzen, 1975 or “enzyme immunoassay", Gyorizuphan, "protein nucleic acid enzymes", Special Issue 31, 1987), and the like. The same two is done with a crosslinking reagent.
- the sample is applied to the microchip and the sample is in contact with the test area and the standard area through a flow formed in the microchannel.
- the present invention provides a detection kit of a detection object in a sample comprising:
- a support provided with a microchannel (Mi croChanne l) to receive a sample and to react;
- the detection apparatus of the present invention uses the above-described detection method of the object to be detected in the sample of the present invention, and the contents common between the two are omitted in order to avoid excessive complexity of the present specification.
- the apparatus of the present invention will be described in detail for each configuration as follows: Configuration (a): A support provided with a microchannel (micro crochannel)
- the detection device of the present invention includes a support for receiving a sample and forming a reaction. Included.
- the support is provided with a microchannel for receiving an analytical sample, the microchannel may have a variety of depth (depth).
- the microchip capable of accommodating an analyte sample may include one or more microchannels, and the microchannels may be combined with the same compound and a detection antibody that detect different targets.
- the microchannel may include a sample zone, a reaction zone, a competitor carrier complex zone, a test zone, a standard zone, and a reaction termination zone.
- each of the zones may include a sample zone, a reaction zone, a competitor carrier complex zone, a test zone, a standard zone. It can be located in the order of the zone and the end zone.
- the microchannel may include a sample inlet for injecting a sample, and when the sample is introduced into the microchannel through the inlet, the microchannel is bound or non-binding to binding equivalents located in the test zone while passing through the microchannel. Combined.
- a specific reaction of the analyte such as a labeling reaction using a fluorescent material or an antigen-antibody reaction, is performed in a microchannel.
- a specific reaction of the analyte such as a labeling reaction using a fluorescent material or an antigen-antibody reaction
- a microchannel for detection of the detection target, a specific reaction of the analyte, such as a labeling reaction using a fluorescent material or an antigen-antibody reaction, is performed in a microchannel.
- a specific reaction of the analyte such as a labeling reaction using a fluorescent material or an antigen-antibody reaction.
- the competitor carrier complex region is formed in one region of the microchannel, and the same carrier having the same binding properties as the detection target is bound and a competitor carrier complex capable of generating a signal is bound. It is designed to be.
- the competitor carrier composite zone is located upstream of the test zone on the support.
- the test region is formed in one region of the microchannel, and has a binding property that is the same as that of the detection target and binds a binder that binds specifically to the detection target.
- the binding equivalents that can be combined with are designed to be combined.
- the detection object in the sample binds to the bridge complex, and the bridge complex in which the detection object in the sample is bound does not bind to the same binder on the support and a signal is not generated on the support. And when the detection object is not present in the sample, the bridge complex is bound to the same binder on the support and the competitor carrier complex is bound to the bridge complex to generate a signal on the support.
- a support included in the detection apparatus of the present invention includes (i) a sample zone, (ii) a competitor carrier complex zone and (iii) a test zone, wherein the three zones are in fluid flow order Located on the support
- the detection device of the present invention may further include a reference zone formed at one portion of the microchannel and having a reference substance bound to the surface to which a detection target or the same binding substance specifically binds. have.
- the device may include, as a reference material, a detection antibody that binds a label that generates a detectable signal and specifically binds the detection target or the same binding material.
- the apparatus may further include measuring means for measuring a signal generated from the label, or the apparatus may include analyzing means for calculating a ratio of the intensity of the signal measured in the test area and the standard area. It may further include.
- the method and apparatus of the present invention can be used in a variety of ways, for example, when detecting hormones that are micromolecules, by effectively dissociating non-target proteins and binding hormones into a free hormone state in the sample, excellent resolution or resolution ( By providing a resolut ion, the object to be detected in the sample can be separated into a fine concentration range.
- the present invention relates to a novel detection method of a detection target in a sample and a detection apparatus using the same.
- the detection method of the present invention can improve the reactivity by inducing the binding reaction between the antibody and the detection object by using the 'bridge complex' in which the gold nanoparticles and the antibody specific to the detection object are bound.
- the method of the present invention can effectively detect small molecules of small molecular weight such as hormones and vitamins. [Brief Description of Drawings]
- FIG. 1 schematically shows a detection method of the present invention.
- Figure 2 measures the degree of dissociation (displacement) according to the concentration of testosterone.
- 2A shows a calibration curve according to the conventional detection methods 1 and 2 without using gold nanoparticles
- FIG. 2B shows a calibration curve according to the method of the present invention using gold nanoparticles.
- the horizontal axis represents the ratio of the test intensity signal to the reference intensity signal
- the vertical axis represents the concentration of testosterone.
- FIG. 3 shows the correlation according to the detection method.
- Figure 3a shows the correlation according to the conventional detection method 1 and 2 (Figs. 6a and 6b)
- Figure 3b shows the correlation according to the conventional detection method 3 (Fig. 6c)
- Figure 3c shows the method of the present invention Correlation according to In the case of FIG. 3A, the correlation was low as 0.7414.
- FIG. 3B the correlation was high, but it requires a separate washing process. In the case of the present invention, it does not go through the washing process and the correlation was also found to be high.
- 5A shows a calibration curve according to the conventional detection methods 1 and 2 without using gold nanoparticles
- FIG. 5B shows a calibration curve according to the method of the present invention using gold nanoparticles.
- FIG. 6a to 6c show a testosterone detection method using the detection apparatus of the present invention using the conventional testosterone detection method (respective reactions 1, 2 and 3, respectively).
- Samples represent blood (a: sample inlet, b: competitor carrier complex zone, c: test zone, d: standard zone). * Abbreviation
- Ant i-Testosterone F.B. Ant i -Testosterone Fluorescence bead Tes t O-3CM0 : BSA-® : Testosterone ⁇ 3 ⁇ carboxymethyloxime ⁇ bovine serum albumin-Biot in
- Ant i -Testosterone-® Ant i-Testosterone-Biot in
- Gold nanoparticles (Go Id nanopart icle) of about 40 nm in diameter and antibodies (anti-testosterone or anti-Vi tamin D) were mixed in a constant ratio in a test tube and reacted at room temperature for 1 hour. The antibody was added so that the final concentration was 5 y g / mL.
- BSA bovine serum albumin
- phosphate buffer PB buf fer
- the activated fluorescent microparticles and antigen [Testosterone-3-carboxymethyloxime-bovine serum albumin, Testosterone—3-CM0-BSA) or vitamin D] were then added at a constant rate in the test tube. After mixing (100 uL of 2% fluorescent microparticles and 250 ug of antigen), the mixture was reacted at room temperature for 2 hours.
- Example 3 Biotinylation of Testosterone 3CM0 BSA
- Testosterone 3CM0 BSA was mixed with biotin (biot in) at a rate and reacted at room temperature for 1 hour (20 mol biotin / 1 mol antibody).
- Biotinylated-Testosterone or Biotinylated-Vi tamin D is dotted onto the lower substrate of the chip with avidin and then at room temperature It was time to react.
- the detection method of the present invention was found to be wider range and dissociation degree (Di s.%) Of the average value of the measured signal. Table 3
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Endocrinology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2016569433A JP6386591B2 (ja) | 2014-05-23 | 2015-05-22 | 新規な試料内検出対象物の検出方法及びこれを利用した検出キット |
EP15795399.3A EP3147371B1 (en) | 2014-05-23 | 2015-05-22 | Novel method for detecting detection object in sample, and detection kit using same |
US15/313,382 US10495633B2 (en) | 2014-05-23 | 2015-05-22 | Method for detecting detection object in sample, and detection kit using same |
CN201580027380.0A CN106460056B (zh) | 2014-05-23 | 2015-05-22 | 试样内检测对象物的检测方法及利用其的检测试剂盒 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2014-0062143 | 2014-05-23 | ||
KR1020140062143A KR101548284B1 (ko) | 2014-05-23 | 2014-05-23 | 신규한 시료 내 검출대상물의 검출방법 및 그를 이용한 검출키트 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2015178729A1 true WO2015178729A1 (ko) | 2015-11-26 |
Family
ID=54062239
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2015/005191 WO2015178729A1 (ko) | 2014-05-23 | 2015-05-22 | 신규한 시료 내 검출대상물의 검출방법 및 그를 이용한 검출키트 |
Country Status (6)
Country | Link |
---|---|
US (1) | US10495633B2 (ko) |
EP (1) | EP3147371B1 (ko) |
JP (1) | JP6386591B2 (ko) |
KR (1) | KR101548284B1 (ko) |
CN (1) | CN106460056B (ko) |
WO (1) | WO2015178729A1 (ko) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3387447A4 (en) * | 2015-12-11 | 2019-08-28 | Opko Diagnostics, LLC | FLUID SYSTEMS WITH INCUBATION SAMPLES AND / OR REAGENTS |
CN108982880A (zh) * | 2018-05-31 | 2018-12-11 | 湖南远璟生物技术有限公司 | 一种睾酮磁微粒化学发光免疫定量检测试剂盒及其制备方法 |
CN113533012B (zh) * | 2020-04-22 | 2024-03-12 | 上海云泽生物科技有限公司 | 用于伏立康唑血药浓度检测的样本前处理液 |
CN113504379A (zh) * | 2021-07-28 | 2021-10-15 | 北京乐普诊断科技股份有限公司 | 一种性激素解离剂及检测试剂盒 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20030055483A (ko) * | 2001-12-26 | 2003-07-04 | 한국전자통신연구원 | 경쟁 결합을 이용하는 바이오센서와 이를 이용한 생화학시료 검출 장치 및 방법 |
KR20130034078A (ko) * | 2011-09-28 | 2013-04-05 | 광주과학기술원 | 조류독소 검출용 고감도 형광 면역 센서 및 이를 이용한 조류독소의 경쟁적 형광 면역 분석방법 |
KR20130095530A (ko) * | 2012-02-20 | 2013-08-28 | 주식회사 나노엔텍 | 신규한 항원의 검출방법 및 그를 이용한 장치 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA1073351A (en) | 1976-02-02 | 1980-03-11 | Nuclear-Medical Laboratories | Competitive thyroid hormone radio assay in a single tube |
US4650770A (en) * | 1981-04-27 | 1987-03-17 | Syntex (U.S.A.) Inc. | Energy absorbing particle quenching in light emitting competitive protein binding assays |
AU1449092A (en) | 1992-02-24 | 1993-09-13 | Triton Diagnostics, Inc. | Bridge immunoassay |
US6541213B1 (en) * | 1996-03-29 | 2003-04-01 | University Of Washington | Microscale diffusion immunoassay |
US20090214420A1 (en) * | 2005-04-01 | 2009-08-27 | Medvet Science Pty. Ltd. | Method of Diagnosis and Treatment and Agents Useful for Same |
KR101396673B1 (ko) | 2006-11-02 | 2014-05-16 | 교와 메덱스 가부시키가이샤 | 측정 대상 성분의 면역 측정법 |
WO2010009438A1 (en) | 2008-07-17 | 2010-01-21 | Andreas Pfuetzner | Biomarkers for insulin resistance and beta-cell dysfunction |
US20120220051A1 (en) * | 2009-07-08 | 2012-08-30 | Anp Technologies, Inc. | Immunogenicity Assay |
JP5997446B2 (ja) | 2011-02-03 | 2016-09-28 | アークレイ株式会社 | 甲状腺ホルモン固定化担体の液体試薬およびその用途 |
MY174877A (en) | 2011-11-16 | 2020-05-20 | Adrenomed Ag | Anti-adrenomedullin (adm) antibpdy or anti-adm antibody fragment of anti-adm non-ig scaffold for prevention or reduction of organ dysfunction or organ failure in a patient having a chronic of acute disease or acute condition |
-
2014
- 2014-05-23 KR KR1020140062143A patent/KR101548284B1/ko active IP Right Grant
-
2015
- 2015-05-22 EP EP15795399.3A patent/EP3147371B1/en active Active
- 2015-05-22 JP JP2016569433A patent/JP6386591B2/ja active Active
- 2015-05-22 CN CN201580027380.0A patent/CN106460056B/zh active Active
- 2015-05-22 US US15/313,382 patent/US10495633B2/en active Active
- 2015-05-22 WO PCT/KR2015/005191 patent/WO2015178729A1/ko active Application Filing
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20030055483A (ko) * | 2001-12-26 | 2003-07-04 | 한국전자통신연구원 | 경쟁 결합을 이용하는 바이오센서와 이를 이용한 생화학시료 검출 장치 및 방법 |
KR20130034078A (ko) * | 2011-09-28 | 2013-04-05 | 광주과학기술원 | 조류독소 검출용 고감도 형광 면역 센서 및 이를 이용한 조류독소의 경쟁적 형광 면역 분석방법 |
KR20130095530A (ko) * | 2012-02-20 | 2013-08-28 | 주식회사 나노엔텍 | 신규한 항원의 검출방법 및 그를 이용한 장치 |
Non-Patent Citations (1)
Title |
---|
See also references of EP3147371A4 * |
Also Published As
Publication number | Publication date |
---|---|
CN106460056B (zh) | 2020-11-17 |
JP2017517732A (ja) | 2017-06-29 |
KR101548284B1 (ko) | 2015-08-28 |
US10495633B2 (en) | 2019-12-03 |
EP3147371A1 (en) | 2017-03-29 |
CN106460056A (zh) | 2017-02-22 |
JP6386591B2 (ja) | 2018-09-05 |
EP3147371B1 (en) | 2022-12-28 |
US20170184572A1 (en) | 2017-06-29 |
EP3147371A4 (en) | 2017-11-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10732111B2 (en) | Automated immunoanalyzer system for performing diagnostic assays for allergies and autoimmune diseases | |
Zhao et al. | Chemiluminescence immunoassay | |
EP2380026B1 (en) | Assay for troponin i using magnetic labels | |
RU2608656C2 (ru) | Связанные со стрептавидином магнитные частицы и способ их изготовления | |
CN110763834B (zh) | 一种检测免疫标志物含量的方法、试剂和试剂盒 | |
CN109709317B (zh) | 一种无基质效应的均相免疫检测试剂盒及其分析方法和应用 | |
JPH11507437A (ja) | 準ゼプトモルの量の分析物を検出または定量化するための光学的トラップ | |
WO2006128362A1 (fr) | Procede et kit correspondant destines a la detection quantitative d’un analyte specifique avec un agent de capture unique | |
EP2952880B1 (en) | Test substance measurement kit and test substance measurement method | |
JP6386591B2 (ja) | 新規な試料内検出対象物の検出方法及びこれを利用した検出キット | |
EP3425394A1 (en) | Kit for determining quantity of bile acid in biological sample and method for determining quantity of bile acid in biological sample | |
EP2639584A1 (en) | Real time diagnostic assays using an evanescence biosensor | |
EP3679856A1 (en) | Chromatographic strip comprising multiple test lines, diagnostic kit comprising same, and qualitative, semi-quantitative or quantitative analysis method comprising multiple competitive reaction measurement steps | |
EP3435082B1 (en) | Detection of multiple analytes | |
JP2010281595A (ja) | リガンド分子の検出方法 | |
WO2024001798A1 (zh) | 一种基于核酸适体的细胞外囊泡荧光极化检测方法及应用 | |
CN109781972B (zh) | 一种免疫定量检测方法和应用 | |
KR20090065139A (ko) | 광분해성 올리고머를 이용한, 복수의 생체분자에 대한신호의 동시 검출 방법 | |
JP5137880B2 (ja) | 結合性物質を固定化した乾燥粒子の製造方法 | |
US20120258882A1 (en) | Method for quantitatively detecting biomolecules | |
JP2004012176A (ja) | 蛋白質検出方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 15795399 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 15313382 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2016569433 Country of ref document: JP Kind code of ref document: A |
|
REEP | Request for entry into the european phase |
Ref document number: 2015795399 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2015795399 Country of ref document: EP |